We are on a mission to elevate patient care in breast cancer and beyond.
With nearly 2 million new diagnoses annually, breast cancer is the second most prevalent cancer worldwide. Up to 30% of people diagnosed with breast cancer ultimately develop metastatic disease.
Like many people and families, much of our team has been personally affected by this disease, fueling our collective passion to create more effective, safe, and convenient treatments to help people living with cancer feel better, longer. Meet our team of oncology experts with a track record of bringing disruptive new therapies to market.
Our team
Sean P. Bohen, M.D., Ph.D.
Sean Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. Dr. Bohen is also a non-executive director of AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.
Ian Clark
Ian Clark has served as a member of the Board of Directors since August 2020. Mr. Clark most recently served as Chief Executive Officer and Board member of Genentech, Inc. Prior to that, Mr. Clark held several senior management positions at Genentech/Roche, including Head of Global Product Strategy, Executive Vice President, Commercial Operations, and Senior Vice President and General Manager of BioOncology. Prior to that, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals, and G.D. Searle. Mr. Clark serves as a member of the Boards of Directors of Takeda Pharmaceutical Company Limited, Kyverna Therapeutics, Inc., Corvus Pharmaceuticals, Inc., and Guardant Health, Inc. Previously, he was on the Boards of AVROBIO, Inc., Shire Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Forty Seven Inc., and Kite Pharma, Inc. Mr. Clark is currently an advisor to KKR & Co. Inc., and previously served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. Mr. Clark received his B.S. in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
Cindy Butitta
Cindy Butitta has served as a member of the Board of Directors since August 2020. She most recently served as Chief Financial Officer and then as Chief Operating Officer of Kite Pharma Inc. Before Kite, Ms. Butitta was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals, Inc. Earlier in her career, she held roles of increasing leadership at Telik, Inc., including Chief Operating Officer, Chief Financial Officer, and Principal Accounting Officer. She is a member of the Boards of Directors of Autolus Therapeutics plc, Century Therapeutics, and UroGen Pharma Ltd. Ms. Butitta received a B.S. with honors in business and accounting from Edgewood College in Madison, Wisconsin, and an M.B.A. in finance from the University of Wisconsin, Madison.
Scott Garland
Scott Garland has served as a member of the Board of Directors since October 2023. He most recently served as CEO of PACT Pharma, an immuno-oncology company that was focused on developing cell therapies for solid tumors. Prior to PACT, Mr. Garland was president and chief executive officer of Portola Pharmaceuticals where he led the company through the commercial launch of Andexxa® and a successful acquisition by Alexion. Before joining Portola, he was at Relypsa where he served first as chief commercial officer and then as president of the U.S. organization after the company was acquired by Vifor Pharma. Prior to Relypsa, he was chief commercial officer at Exelixis where he led the launch of cabozantinib. Mr. Garland has held numerous other commercial leadership roles at Genentech, Amgen and Merck, including leading the commercial franchises for two multi-billion-dollar therapies – Avastin® and Rituxan®. Mr. Garland currently serves as a board member for ALX Oncology, Day One Biopharmaceuticals, and LB Pharmaceuticals, Inc . Mr. Garland received a B.S. from California Polytechnic State University-San Luis Obispo and an MBA from the Fuqua School of Business at Duke University.
Cyrus Harmon, Ph.D.
Cyrus Harmon is a co-founder of Olema Oncology and has served as a member of the Board of Directors since August 2006. Dr. Harmon is currently the President and Chief Executive Officer of Vilya, Inc., a computational biotechnology company. During his time at Olema, he served as Chief Research Officer and Chief Technology Officer from September 2020 through March 2023, and as President and Chief Executive Officer from March 2007 to September 2020. Before Olema, he was Vice President of Computational Genomics and General Manager at Affymetrix, Inc., which was acquired by Thermo Fisher Scientific. He founded and served as Chief Executive Officer of Neomorphic, Inc., which was acquired by Affymetrix, Inc. Dr. Harmon received a B.A. and Ph.D. in molecular and cell biology from the University of California, Berkeley.
Sandra J. Horning, M.D., FACP, FASCO
Sandra Horning has served as a member of the Board of Directors since November 2020. Dr. Horning served as the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2014 until her retirement in 2019, and prior to that as Roche’s Global Head of Oncology Product Development. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. In addition to serving on editorial boards, the FDA Oncology Drugs Advisory Committee and authoring more than 300 publications in peer-reviewed medical journals, Dr. Horning has received numerous awards and recognition throughout her career, including the Healthcare Businesswomen’s Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award, Fellow of the American College of Physicians and Fellow of the American Society of Clinical Oncology. She currently serves on the Boards of Directors of Gilead Sciences, Inc., Moderna, Inc., Revolution Medicines, Inc., and Cellarity. Dr. Horning received an M.D. from the University of Iowa School of Medicine and completed a post-graduate oncology clinical fellowship at Stanford University.
Gorjan Hrustanovic, Ph.D.
Gorjan Hrustanovic has served as a member of the Board of Directors since July 2018. He is a Managing Director at BVF Partners L.P. Dr. Hrustanovic also serves on the Board of Directors of Kymera Therapeutics Inc., Plexium Therapeutics, and Forward Therapeutics., and previously Nimbus Therapeutics and Rain Oncology. Dr. Hrustanovic received a B.S. in molecular biology and a B.S. in management science from the University of California, San Diego, and a Ph.D. in cancer biology and cell signaling from the University of California, San Francisco.
Yi Larson, MBA
Yi Larson has served as a member of the Board of Directors since April 2021. Ms. Larson previously served as the Chief Financial Officer of LianBio, and before that, she was Executive Vice President and Chief Financial Officer of Turning Point Therapeutics, Inc. Prior to Turning Point, Ms. Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years. She advised senior management teams and boards on a range of strategic and financial matters, successfully executing over 50 deals, including $70 billion in M&A activities and $30 billion in financings. She previously served as a member of the board of directors of RayzeBio, Inc., a targeted radiopharmaceuticals company, from April 2021 until its acquisition by Bristol Myers Squibb in February 2024. Ms. Larson earned an MBA, concentrated in Finance, from The Wharton School at the University of Pennsylvania. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from the Massachusetts Institute of Technology (MIT).
Andy Rappaport
Andy Rappaport has served as a member of the Board of Directors since January 2013. He is the Managing Partner at Skyline Public Works, LLC, his family office, Managing Partner and Chief Investment Officer of SPW Investments, his family investment vehicle, and serves on the Board of Directors of Groq, Inc. Earlier, he was a partner at August Capital and President of the Technology Research Group, a global strategy consulting firm he founded.
Graham Walmsley, M.D., Ph.D.
Graham Walmsley has served as a member of the Board of Directors since March 2020. Dr. Walmsley is a Co-Founder and Managing Partner of Logos Global Management, LP. Previously, he served as a Principal of Versant Ventures, as well as Head of Business Development of Jecure Therapeutics, Inc., until its acquisition by Genentech Inc. He is a member of the Board of Directors of Akero Therapeutics. Dr. Walmsley received a B.A. in molecular and cell biology from the University of California, Berkeley, and a Ph.D. and an M.D. in stem cell biology and regenerative medicine from Stanford University School of Medicine.